【摘要】 目的：探讨氯氮平联合齐拉西酮治疗精神分裂症患者的效果。方法：选择2021年6月—2023年8月黄山市第二人民医院收治的80例精神分裂症患者作为研究对象，通过随机数表法将患者分为对照组与观察组，各40例。对照组采用氯氮平联合利培酮治疗，观察组采用氯氮平联合齐拉西酮治疗，比较两组精神状况[简明精神病评定量表（BPRS）、社会功能缺陷量表（SDSS）、治疗时出现的症状量表（TESS）]、肾功能指标、血脂水平、血清水平及糖代谢。结果：两组治疗前SDSS评分、血脂水平、载脂蛋白B（Apo-B）水平、糖代谢指标比较，差异无统计学意义（P>0.05）；观察组治疗后SDSS评分、TESS评分、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、Apo-B、前白蛋白（PA）、糖化血清蛋白（GSP）、空腹血糖（FBG）低于对照组，高密度脂蛋白胆固醇（HDL-C）高于对照组，差异有统计学意义（P<0.05）。两组治疗前后BPRS评分、尿素氮（BUN）、肌酐（Cr）、尿酸（UA）、载脂蛋白A₁（Apo-A₁）、β₂-微球蛋白（β₂-MG）比较，差异无统计学意义（P>0.05）。结论：在精神分裂症患者治疗中，氯氮平联合齐拉西酮与氯氮平联合利培酮的疗效相近，但氯氮平联合齐拉西酮能显著改善患者的SDSS评分和TESS评分，优化血脂水平和糖代谢指标，降低心血管疾病风险，且对肾功能无明显不良影响。更多还原

【Abstract】 Objective:To explore the effect of Clozapine combined with Ziprasidone in the treatment of patients with schizophrenia.Method:A total of 80 patients with schizophrenia who treated in the Second People’s Hospital of Huangshan City from June 2021 to August 2023 were selected as the research subjects,the patients were divided into the control group and the observation group by random number table method,with 40 patients in each group.The control group received Clozapine combined with Risperidone treatment,while the observation group received Clozapine combined with Ziprasidone treatment.The mental status[brief psychiatric rating scale （BPRS）,social dysfunction screening schedule （SDSS）,treatment emergent symptom scale （TESS）],renal function indicators,lipid levels,serum levels and glucose metabolism were compared of two groups.Result:There were no significant differences in the SDSS score,blood lipid level,apolipoprotein B （Apo-B） level and glucose metabolism indexes between two groups before treatment （P>0.05）;after treatment,the SDSS score,TESS score,total cholesterol （TC）,triglyceride （TG）,low density lipoprotein cholesterol （LDL-C）,Apo-B,prealbumin （PA）,glycosylated serum protein （GSP） and fasting blood glucose （FBG） in the observation group were lower than those in the control group,and the high density lipoprotein cholesterol （HDL-C） was higher than that in the control group,the differences were statistically significant （P<0.05）.There were no significant differences in BPRS score,urea nitrogen （BUN）,creatinine （Cr）,uric acid （UA）,apolipoprotein A₁ （Apo-A₁） and β₂-microglobulin （β₂-MG） between two groups before and after treatment （P>0.05）.Conclusion:In the treatment of patients with schizophrenia,Clozapine combined with Ziprasidone and Clozapine combined with Risperidone show similar efficacy,but Clozapine combined with Ziprasidone can significantly improve the SDSS score and TESS score of patients,optimize blood lipid levels and glucose metabolism indexes,reduce the risk of cardiovascular disease,and have no significant adverse effects on renal function.更多还原